On Monday September 26, the Department of Justice announced a settlement resolving a lawsuit filed by former employee Michael Bawduniak (the “Plaintiff”) against Biogen Inc. (the “Company”) under the qui tam provisions of the federal False Claims Act.[1]
About
Dominick DiSabatino is a partner on the Life Sciences team in the firm's Washington, D.C. office.
More Posts
Charging for Investigational Drugs Under an IND Questions and Answers, Draft Guidance for Industry, August 2022
FDA Issues Untitled Letter to Althera Pharmaceuticals for Statements Relating to ROSZET®
FDA Issues Untitled Letter to Bausch Health Companies for Misleading Statements Relating to DUOBRII™
OIG Advisory Opinion Alert: Yet Another Favorable Decision for Medical Device Manufacturers
OIG Advisory Opinion Alert: Yet Another Favorable Decision for Medical Device Manufacturers
About
Dominick DiSabatino is a partner on the Life Sciences team in the firm's Washington, D.C. office.